UPMC in Pennsylvania is one of the first health systems to write a blueprint for treating patients experiencing gruesome side effects from drugs laced with xylazine. The UPMC team published the guidelines in the Substance Use and Addiction Journal to share the easy-to-follow roadmap for other hospitals to use.
